AC Immune SA (NASDAQ:ACIU) Short Interest Up 23.5% in October

AC Immune SA (NASDAQ:ACIU) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 984,500 shares, an increase of 23.5% from the October 15th total of 796,900 shares. Approximately 1.6% of the company’s stock are sold short. Based on an average trading volume of 92,100 shares, the short-interest ratio is currently 10.7 days.

Wall Street Analysts Forecast Growth

ACIU has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of AC Immune in a report on Wednesday, November 6th. StockNews.com downgraded AC Immune from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its holdings in AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock worth $72,000 after acquiring an additional 7,400 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of AC Immune in the second quarter worth $218,000. Renaissance Technologies LLC lifted its holdings in shares of AC Immune by 26.4% during the second quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock valued at $2,602,000 after purchasing an additional 136,300 shares in the last quarter. Vanguard Capital Wealth Advisors purchased a new stake in shares of AC Immune during the second quarter valued at $56,000. Finally, Assenagon Asset Management S.A. increased its holdings in AC Immune by 294.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock worth $1,755,000 after buying an additional 328,312 shares in the last quarter. Institutional investors own 51.36% of the company’s stock.

AC Immune Price Performance

Shares of AC Immune stock opened at $3.55 on Friday. The stock has a market cap of $351.24 million, a price-to-earnings ratio of -7.72 and a beta of 1.28. AC Immune has a 1 year low of $2.25 and a 1 year high of $5.14. The firm’s 50-day moving average is $3.27 and its 200 day moving average is $3.47.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.